

Emmanuel Androulakis

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1841501/emmanuel-androulakis-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

1,165
citations

16
h-index

33
g-index

71
ext. papers

1,355
ext. citations

3.7
avg, IF

4.26
L-index

#	Paper	IF	Citations
61	Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 667-76	15.1	199
60	White-coat hypertension and cardiovascular events: a meta-analysis. <i>Journal of Hypertension</i> , 2016 , 34, 593-9	1.9	101
59	The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. <i>Heart Failure Reviews</i> , 2016 , 21, 169-76	5	92
58	Pathophysiology of atherosclerosis: the role of inflammation. <i>Current Pharmaceutical Design</i> , 2011 , 17, 4089-110	3.3	86
57	Socioeconomic status and risk factors for cardiovascular disease: Impact of dietary mediators. <i>Hellenic Journal of Cardiology</i> , 2017 , 58, 32-42	2.1	80
56	Essential hypertension: is there a role for inflammatory mechanisms?. <i>Cardiology in Review</i> , 2009 , 17, 216-21	3.2	62
55	Fibrinogen and cardiovascular disease: genetics and biomarkers. <i>Blood Reviews</i> , 2011 , 25, 239-45	11.1	45
54	Oxidative stress and early atherosclerosis: novel antioxidant treatment. <i>Cardiovascular Drugs and Therapy</i> , 2015 , 29, 75-88	3.9	42
53	Inflammatory markers in essential hypertension: potential clinical implications. <i>Current Vascular Pharmacology</i> , 2010 , 8, 509-16	3.3	36
52	Inflammation in hypertension: current therapeutic approaches. <i>Current Pharmaceutical Design</i> , 2011 , 17, 4121-31	3.3	29
51	From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand. <i>Trends in Cardiovascular Medicine</i> , 2010 , 20, 153-64	6.9	29
50	Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease. <i>Amino Acids</i> , 2015 , 47, 1741-50	3.5	24
49	Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies. <i>Heart Failure Reviews</i> , 2012 , 17, 65-79	5	19
48	Antioxidant treatment and endothelial dysfunction: is it time for flavonoids?. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2013 , 8, 81-92		19
47	Clinical utility of biomarkers in premature atherosclerosis. <i>Current Medicinal Chemistry</i> , 2012 , 19, 2521-33	3.3	17
46	Improving the detection of preclinical organ damage in newly diagnosed hypertension: nocturnal hypertension versus non-dipping pattern. <i>Journal of Human Hypertension</i> , 2015 , 29, 689-95	2.6	16
45	Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease. <i>Current Topics in Medicinal Chemistry</i> , 2012 , 12, 1214-21	3	16

44	Prognostic role of miRNAs in coronary artery disease. <i>Current Topics in Medicinal Chemistry</i> , 2013 , 13, 1540-7	3	16
43	Matrix metalloproteinases in acute coronary syndromes: current perspectives. <i>Current Topics in Medicinal Chemistry</i> , 2012 , 12, 1192-205	3	14
42	Imaging Subclinical Atherosclerosis: Where Do We Stand?. <i>Current Cardiology Reviews</i> , 2017 , 13, 47-55	2.4	13
41	The Role of Cardiovascular Magnetic Resonance in Sports Cardiology; Current Utility and Future Perspectives. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018 , 20, 86	2.1	13
40	Statins and inflammation in cardiovascular disease. <i>Current Pharmaceutical Design</i> , 2017 ,	3.3	12
39	The role of matrix metalloproteinases in essential hypertension. <i>Current Topics in Medicinal Chemistry</i> , 2012 , 12, 1149-58	3	12
38	Novel therapeutic strategies in the management of arterial hypertension. <i>Pharmacology & Therapeutics</i> , 2012 , 135, 168-75	13.9	11
37	Combined effects of fibrinogen genetic variability on atherosclerosis in patients with or without stable angina pectoris: focus on the coagulation cascade and endothelial function. <i>International Journal of Cardiology</i> , 2013 , 168, 4602-7	3.2	11
36	Novel therapeutic strategies targeting vascular endothelium in essential hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1395-412	5.9	10
35	Novel biomarkers assessing endothelial dysfunction: role of microRNAs. <i>Current Topics in Medicinal Chemistry</i> , 2013 , 13, 1518-26	3	10
34	Subclinical Organ Damage in White-Coat Hypertension: The Possible Role of Cystatin C. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 190-197	2.3	9
33	Lifestyle factors and endothelial function. <i>Current Vascular Pharmacology</i> , 2012 , 10, 94-106	3.3	9
32	Genetic predisposition to left ventricular hypertrophy and the potential involvement of cystatin-C in untreated hypertension. <i>American Journal of Hypertension</i> , 2013 , 26, 683-90	2.3	8
31	Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment. <i>Current Pharmaceutical Design</i> , 2018 , 24, 4424-4435	3.3	8
30	Meta-Analysis of Oral Anticoagulants with Dual versus Single Antiplatelet Therapy in Patients after Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2016 , 16, 103-10	4	7
29	HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation. <i>Expert Opinion on Therapeutic Targets</i> , 2016 , 20, 907-21	6.4	7
28	Renin-Angiotensin System Inhibitors vs Other Antihypertensives in Hypertensive Blacks: A Meta-Analysis. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 344-350	2.3	7
27	MicroRNAs in the diagnosis and treatment of unstable angina. <i>Current Topics in Medicinal Chemistry</i> , 2013 , 13, 1596-604	3	7

26	Genetic polymorphism M235T of angiotensinogen: effects on endothelial function and arterial stiffness in hypertensives. <i>International Journal of Cardiology</i> , 2012 , 155, 501-3	3.2	6
25	Coronary Artery Atherosclerosis in Hypertensive Patients: The Role of Fibrinogen Genetic Variability. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017 , 70, 34-41	0.7	5
24	Effects of the C-344T aldosterone synthase gene variant on preclinical vascular alterations in essential hypertension. <i>International Journal of Cardiology</i> , 2013 , 168, 1605-6	3.2	5
23	The Impact of Antiplatelet Treatment on Endothelial Function. <i>Current Pharmaceutical Design</i> , 2016 , 22, 4512-4518	3.3	5
22	Genetic variability of matrix metalloproteinase genes in cardiovascular disease. <i>Current Topics in Medicinal Chemistry</i> , 2012 , 12, 1206-13	3	5
21	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. <i>Current Cardiology Reviews</i> , 2017 , 13, 168-182	2.4	4
20	Statins and myocardial infarction: Type, dose, and administration time: Does it matter?. <i>Trends in Cardiovascular Medicine</i> , 2016 , 26, 433-41	6.9	4
19	Insight to the Pathophysiology of Stable Angina Pectoris. <i>Current Pharmaceutical Design</i> , 2013 , 19, 1593-1600	3.6	3
18	The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque. <i>Current Pharmaceutical Design</i> , 2013 , 19, 1651-1657	3.3	3
17	Heart Rate as a Therapeutic Target in Angina Pectoris. <i>Current Pharmaceutical Design</i> , 2013 , 19, 1562-1568	3.3	3
16	Eosinophilic heart disease: diagnostic and prognostic assessment by cardiac magnetic resonance. <i>European Heart Journal Cardiovascular Imaging</i> , 2021 , 22, 1273-1284	4.1	3
15	Atherosclerosis coronaria en pacientes hipertensos: el papel de la variabilidad genética del fibrinógeno. <i>Revista Espanola De Cardiologia</i> , 2017 , 70, 34-41	1.5	2
14	Genetic Polymorphisms and the Vascular Endothelium 2015 , 129-142		1
13	Hypertrophic cardiomyopathy or athlete's heart? A systematic review of novel cardiovascular magnetic resonance imaging parameters. <i>European Journal of Sport Science</i> , 2021 , 1-12	3.9	1
12	Transcatheter mitral valve repair with MitraClip in patients with pulmonary hypertension: hemodynamic and prognostic perspectives. <i>Reviews in Cardiovascular Medicine</i> , 2021 , 22, 33-38	3.9	1
11	Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. <i>Current Pharmaceutical Design</i> , 2020 , 26, 5953-5968	3.3	0
10	New Drugs and Interventional Strategies for the Management of Hypertension. <i>Current Pharmaceutical Design</i> , 2021 , 27, 1396-1406	3.3	0
9	Chylopericardium associated with constrictive pericarditis assessed by multimodality imaging. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, e04354	0.7	0

8	Spontaneous Coronary Artery Dissection: Insights From Cardiac Magnetic Resonance and Extracoronary Arterial Screening.. <i>Circulation</i> , 2022 , 145, 555-557	16.7	o
7	The Role of Cardiovascular Magnetic Resonance Imaging in the Assessment of Myocardial Fibrosis in Young and Veteran Athletes: Insights From a Meta-Analysis.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 784474	5.4	o
6	Reply. <i>Journal of Hypertension</i> , 2016 , 34, 1658-9	1.9	
5	Chronic thromboembolic pulmonary arterial hypertension: a review of the literature and novel therapeutic approaches. <i>Expert Review of Respiratory Medicine</i> , 2015 , 9, 351-9	3.8	
4	Heart Rate as a Therapeutic Target in Angina Pectoris. <i>Current Pharmaceutical Design</i> , 2013 , 19, 1562-1568	3.8	
3	Novel Biomarkers Used in the Assessment of Acute Coronary Syndrome 2013 , 345-362		
2	C-Reactive Protein in Cardiovascular Disease 2013 , 3-18		
1	Biological therapies targeting arrhythmias: are cells and genes the answer?. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 237-249	5.4	